The treatment group demonstrated a significant reduction in systolic BP ( -10.5 mm Hg ; 95 % CI , -19.9 to -1.1 ; P = .03 ) and serum ACE activity ( -20.4 IU/L ; 95 % CI , -31.0 to -9.8 ; P < .001 ) compared with placebo .